We have characterized their activity both in vitro and in vivo and propose that fenamate NSAIDs can be rapidly repurposed as drugs to target the NLRP3 inflammasome in inflammatory diseases such as Alzheimer's disease. Here, NLRP3 is linked to early-onset autosomal dominant Alzheimer disease.